- Today
- Holidays
- Birthdays
- Reminders
- Cities
- Atlanta
- Austin
- Baltimore
- Berwyn
- Beverly Hills
- Birmingham
- Boston
- Brooklyn
- Buffalo
- Charlotte
- Chicago
- Cincinnati
- Cleveland
- Columbus
- Dallas
- Denver
- Detroit
- Fort Worth
- Houston
- Indianapolis
- Knoxville
- Las Vegas
- Los Angeles
- Louisville
- Madison
- Memphis
- Miami
- Milwaukee
- Minneapolis
- Nashville
- New Orleans
- New York
- Omaha
- Orlando
- Philadelphia
- Phoenix
- Pittsburgh
- Portland
- Raleigh
- Richmond
- Rutherford
- Sacramento
- Salt Lake City
- San Antonio
- San Diego
- San Francisco
- San Jose
- Seattle
- Tampa
- Tucson
- Washington
BridgeBio Pharma CEO Sells $2.98M in Stock
The transaction represents a 6.10% decrease in the CEO's position.
Apr. 13, 2026 at 11:06pm
Got story updates? Submit your updates here. ›
The CEO's sale of nearly $3 million in BridgeBio stock reflects the complex financial machinery behind biopharmaceutical leadership and investment.Palo Alto TodayBridgeBio Pharma, Inc. (NASDAQ:BBIO) CEO Neil Kumar sold 40,000 shares of the company's stock on April 9th, 2026 for a total transaction value of $2,984,800. Following the sale, Kumar directly owns 615,686 shares of BridgeBio Pharma stock, valued at $45,942,489.32. This transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Why it matters
The sale by BridgeBio's CEO represents a significant decrease in his personal stake in the company, potentially signaling a shift in his confidence or plans for the business. Insider transactions like this can provide insights into a company's future direction and are closely watched by investors.
The details
The shares were sold at an average price of $74.62, representing a 6.10% decrease in Kumar's position. This is the fourth time Kumar has sold a large block of BridgeBio shares in the past year, suggesting an ongoing effort to diversify his personal holdings.
- The transaction took place on Thursday, April 9th, 2026.
The players
Neil Kumar
The CEO and co-founder of BridgeBio Pharma, Inc.
BridgeBio Pharma, Inc.
A clinical-stage biopharmaceutical company headquartered in Palo Alto, California that is dedicated to discovering, developing and delivering transformative medicines for patients with genetic diseases and cancers.
What they’re saying
“The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.”
— Neil Kumar, CEO
The takeaway
The sale of $2.98 million in BridgeBio stock by the CEO, while not unexpected given the company's pre-arranged trading plan, still raises questions about his long-term outlook for the business. Investors will be closely watching for any further insider transactions that could signal a shift in the company's strategic direction.
